Zhengye Biotechnology Holding Limited Ordinary Shares
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for househol… Read more
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) - Total Liabilities
Latest total liabilities as of June 2025: $140.71 Million USD
Based on the latest financial reports, Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has total liabilities worth $140.71 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhengye Biotechnology Holding Limited Ordinary Shares - Total Liabilities Trend (2021–2025)
This chart illustrates how Zhengye Biotechnology Holding Limited Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhengye Biotechnology Holding Limited Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Zhengye Biotechnology Holding Limited Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Generic Gold Corporation
PINK:GGCPF
|
USA | $258.22K |
|
Nationwide RV & Resorts, Inc.
PINK:NWRV
|
USA | $2.08 Million |
|
Afrimat
JSE:AFT
|
South Africa | ZAC4.82 Billion |
|
K2 Asset Management Holdings Ltd
AU:KAM
|
Australia | AU$2.93 Million |
|
BIG Industries Bhd
KLSE:7005
|
Malaysia | RM17.55 Million |
|
Sofwave Medical Ltd
TA:SOFW
|
Israel | ILA18.95 Million |
|
P3 Health Partners Inc
NASDAQ:PIII
|
USA | $664.64 Million |
|
Indah Prakasa Sentosa PT Tbk
JK:INPS
|
Indonesia | Rp283.96 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down Zhengye Biotechnology Holding Limited Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhengye Biotechnology Holding Limited Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhengye Biotechnology Holding Limited Ordinary Shares (2021–2025)
The table below shows the annual total liabilities of Zhengye Biotechnology Holding Limited Ordinary Shares from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $140.71 Million | 0.00% |
| 2024-12-31 | $140.71 Million | -12.40% |
| 2023-12-31 | $160.62 Million | -1.35% |
| 2022-12-31 | $162.81 Million | +28.76% |
| 2021-12-31 | $126.44 Million | -- |